<DOC>
	<DOCNO>NCT01828203</DOCNO>
	<brief_summary>The objective study assess efficacy IV minocycline improve neurological functional outcome acute non-penetrating traumatic spinal cord injury ( SCI ) . The primary hypothesis intravenous minocycline twice daily ( 800 mg initial dose taper 400 mg 100 mg dose administered end day 7 ) administer subject acute traumatic non-penetrating cervical SCI start within 12 hour injury improve motor recovery assess International Standards Neurologic Classification Spinal Cord Injury - ISNCSCI ( a.k.a . ASIA ) neurological examination measure 3 month 1 year post-injury , compare placebo . The secondary hypothesis minocycline treatment also result improvement ASIA sensory improvement , ASIA grade functional outcome assess Spinal Cord Independence Measure ( SCIM ) Short Form 36 ( SF-36 ) , compare placebo . In addition effect minocycline neurological functional outcome SCI expect pronounced subject motor incomplete SCI compare motor compete SCI . A subgroup analysis undertaken examine hypothesis .</brief_summary>
	<brief_title>Minocycline Acute Spinal Cord Injury ( MASC )</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Age 16 Acute traumatic nonpenetrating cervical SCI involve neurological level define ASIA neurological examination C0 C8 result detectable change ASIA motor assessment Patient English speak able provide inform consent Randomization administration first dose ( drug placebo ) within 12 hour injury . History systemic lupus erythematosus ( SLE ) Preexisting hepatic renal disease Tetracycline hypersensitivity Pregnancy breast feeding Isolated radicular motor deficit Significant leucopenia ( white blood cell count &lt; 1‚ÅÑ2 time low limit normal ) screen Elevated liver function test ( AST , ALT , alkaline phosphatase , total bilirubin &gt; 2 time upper limit normal ) screen Presence systemic disease might interfere patient safety , compliance evaluation condition study ( e.g . insulindependent diabetes , Lyme disease , clinically significant cardiac disease , HIV , HTLV1 ) Associated traumatic condition interfere informed consent outcome assessment ( e.g . close head injury , liver contusion ) Known uncorrected severe coronary artery disease evidence active coronary ischemia ( ECG change , positive Troponin ) exclude , may tolerate standardize protocol hemodynamic management</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>minocycline</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>phase 3</keyword>
	<keyword>spinal cord injury</keyword>
</DOC>